Psychiatric Ratings using Intermediate Stratified Markers - Providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD

Project Details

Description

This project aims to develop a quantitative biological approach to the understanding and classification of neuropsychiatric diseases to accelerate the discovery and development of better treatments for patients. As the project coordinator of this EU Innovative Medicine Initiative (IMI) project, we aim to unpick the biological reasons underlying social withdrawal, which is a common early symptom of, Schizophrenia, Alzheimer’s disease and Major Depressive Disorder. The PRISM project started on April 1 2016, and is a EUR €16.5 million public-private cooperation, uniting researchers from European academic centres, and major pharmaceutical companies.
Short titlePsychiatric Ratings using Intermediate Stratified Markers
AcronymPRISM
StatusFinished
Effective start/end date01/04/201630/09/2019